Fallopian tube carcinoma
ICD-10 C57.0 · ICD-11 2C74.Y

Treatment of Advanced Fallopian Tube Carcinoma (FIGO Stage III or IV) in Female Patients with High Likelihood of Optimal Surgical Debulking

This protocol covers the initial management of advanced (FIGO stage III or IV) fallopian tube carcinoma in female patients who are candidates for upfront cytoreductive surgery — specifically those with a high likelihood of achieving optimal debulking and without high perioperative risk.

Clinical Scenario Female patient with advanced fallopian tube carcinoma at FIGO stage III or IV, evaluated to have a high likelihood of achieving optimal surgical cytoreduction, and who does not carry high perioperative risk. Evaluation by a gynecologic oncologist is central to this determination, as skilled surgical expertise is essential to achieving optimal debulking.
Surgical Goal Optimal debulking is defined as residual disease of 1 cm or less in maximum diameter or thickness after cytoreductive surgery.
Treatment Approach — Partial Overview When optimal surgical cytoreduction is achievable, management begins with upfront debulking surgery followed by adjuvant systemic chemotherapy; eligibility for additional agents and maintenance strategies depends on further clinical and molecular factors detailed in the full protocol.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1200/JOP.18.00662

National Comprehensive Cancer Network recommends that any woman with suspected epithelial ovarian cancer be evaluated by a gynecologic oncologist, because optimal surgical debulking by a skilled physician is central to the initial management of patients with advanced, stage III or IV disease.

ASCO states that although primary cytoreductive surgery is preferred for patients with a high likelihood of achieving optimal debulking, women with high perioperative risk or a low likelihood of achieving optimal cytoreduction should receive neoadjuvant chemotherapy followed by possible interval surgery.

For those patients who do undergo upfront cytoreductive surgery, adjuvant chemotherapy includes a platinum doublet, traditionally carboplatin and paclitaxel.

Although the goal of cytoreductive surgery is no gross residual, debulking is considered optimal if residual disease is 1 cm or less in maximum diameter or thickness.

View source ↗